Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activation

Canadian Cancer Trials Group ALC.3 (SWOG 1203) - A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) was centrally activated on September 10, 2013.

The primary objectives of the trial are to:
  • compare event-free survival between patients with AML who receive standard 7+3 or idarubicin and high-dose cytarabine (IA) to patients who receive IA + vorinostat, and;
  • determine whether it is possible to get 60% or more of adults with high-risk AML (by cytogenetics) in first complete remission to allogeneic hematopoietic cell transplantation.